Table 3. JAK inhibitor prior to... | American Society of Hematology

Table 3.

JAK inhibitor prior to allogeneic stem cell transplantation

Reference (first author)	Prospective/retrospective	Conditioning	N	Spleen response	Ruxolitinib discontinuation	Graft failure	GVHDII-IV	TRM	OS
Kröger 2018²⁴	Pros	RIC	12	50%	Day +28	0%	8%	0% 17 mo	100% @ 17 mo
Kadir 2018⁴³	Retro	RIC	46	39%	Varied	4%	37%	23% @ 2 y	72.7 @ 2 y
Gupta 2019⁴⁴	Pros	RIC	21	45%	Prior to conditioning	16%	47%	28% @ 2 y	66% @ 2 y
Salit 2020²³	Pros	RIC/MAC	28	NR	Prior to conditioning	0	78%	23% @ 1 y	86% @ 2 y
Kröger 2021⁴⁵	Retro	RIC/MAC	277	56%	NR	NR	29%	26% @ 1 y	66% @ 1 y
Robin 2021⁴⁶	Pros	RIC	59	46%	Prior to transplant— varied	3%	66%	42% @ 1 y	68% @ 1 y
Ali 2022²⁵	Pros	RIC	18	NR	Day +30	0%	45%	23% @ 1 y	77% @ 1 y

Reference (first author)	Prospective/retrospective	Conditioning	N	Spleen response	Ruxolitinib discontinuation	Graft failure	GVHDII-IV	TRM	OS
Kröger 2018²⁴	Pros	RIC	12	50%	Day +28	0%	8%	0% 17 mo	100% @ 17 mo
Kadir 2018⁴³	Retro	RIC	46	39%	Varied	4%	37%	23% @ 2 y	72.7 @ 2 y
Gupta 2019⁴⁴	Pros	RIC	21	45%	Prior to conditioning	16%	47%	28% @ 2 y	66% @ 2 y
Salit 2020²³	Pros	RIC/MAC	28	NR	Prior to conditioning	0	78%	23% @ 1 y	86% @ 2 y
Kröger 2021⁴⁵	Retro	RIC/MAC	277	56%	NR	NR	29%	26% @ 1 y	66% @ 1 y
Robin 2021⁴⁶	Pros	RIC	59	46%	Prior to transplant— varied	3%	66%	42% @ 1 y	68% @ 1 y
Ali 2022²⁵	Pros	RIC	18	NR	Day +30	0%	45%	23% @ 1 y	77% @ 1 y

GVHD, graft-versus-host disease; MAC, myeloablative conditioning; NR, not reported; Pros, prospective; Retro, retrospective.